US Patent

US9327114 — User-activated self-contained co-packaged iontophoretic drug delivery system

Method of Use · Assigned to Teva Pharmaceuticals International GmbH · Expires 2032-10-08 · 6y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a user-activated self-contained co-packaged iontophoretic drug delivery system for treating a subject.

USPTO Abstract

A user-activated self-contained co-packaged iontophoretic drug delivery system and method of use for treatment of a subject are described.

Drugs covered by this patent

sumatriptan-succinate (SUMATRIPTAN SUCCINATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1328`	—	sumatriptan-succinate

Patent Metadata

Patent number: US9327114
Jurisdiction: US
Classification: Method of Use
Expires: 2032-10-08
Drug substance claim: No
Drug product claim: Yes
Assignee: Teva Pharmaceuticals International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.